Strathmore Announces CSE Listing
Alvotech (NASDAQ: ALVO), a global biotech company focused on biosimilar medicines, has appointed Dr. Balaji V. Prasad as Chief Strategy Officer. Dr. Prasad brings 25 years of pharmaceutical industry experience, combining medical expertise with financial analysis background. He previously served as a director and equities analyst at Barclays, covering US specialty pharma. His credentials include an MD from Bangalore Medical College and an MBA from IIM Ahmedabad.
Prior roles include portfolio management at a Swiss asset management firm and leadership positions at Barclays and Goldman Sachs' India healthcare coverage. Chairman and CEO Róbert Wessman highlighted Dr. Prasad's deep understanding of Alvotech's business and product pipeline as key assets for the company's growth.
Alvotech (NASDAQ: ALVO), un'azienda biotecnologica globale specializzata in medicinali biosimilari, ha nominato Dr. Balaji V. Prasad Chief Strategy Officer. Il Dr. Prasad vanta 25 anni di esperienza nell'industria farmaceutica, unendo competenze mediche a una solida preparazione in analisi finanziaria. In precedenza ha lavorato come direttore e analista azionario presso Barclays, occupandosi del settore farmaceutico specializzato negli Stati Uniti. Tra i suoi titoli figurano un MD conseguito al Bangalore Medical College e un MBA presso l'IIM Ahmedabad.
Tra le sue esperienze precedenti si annoverano la gestione di portafogli in una società svizzera di asset management e ruoli di leadership presso Barclays e nella divisione healthcare di Goldman Sachs in India. Il Presidente e CEO Róbert Wessman ha sottolineato come la profonda conoscenza del Dr. Prasad del business e del pipeline prodotti di Alvotech rappresenti un valore fondamentale per la crescita dell'azienda.
Alvotech (NASDAQ: ALVO), una compañía biotecnológica global enfocada en medicamentos biosimilares, ha nombrado a Dr. Balaji V. Prasad como Director de Estrategia. El Dr. Prasad aporta 25 años de experiencia en la industria farmacéutica, combinando conocimientos médicos con formación en análisis financiero. Anteriormente se desempeñó como director y analista de acciones en Barclays, cubriendo el sector farmacéutico especializado en EE. UU. Posee un MD del Bangalore Medical College y un MBA del IIM Ahmedabad.
Sus roles previos incluyen gestión de portafolios en una firma suiza de gestión de activos y puestos de liderazgo en Barclays y en la cobertura de salud de Goldman Sachs en India. El presidente y CEO Róbert Wessman destacó que el profundo entendimiento del Dr. Prasad sobre el negocio y la cartera de productos de Alvotech es un activo clave para el crecimiento de la compañía.
Alvotech (NASDAQ: ALVO)는 바이오시밀러 의약품에 집중하는 글로벌 바이오텍 기업으로, 발라지 V. 프라사드 박사를 최고전략책임자(Chief Strategy Officer)로 임명했습니다. 프라사드 박사는 25년간 제약 산업에서 의료 전문지식과 금융 분석 역량을 결합한 경험을 보유하고 있습니다. 이전에는 바클레이즈에서 미국 전문 제약 분야를 담당하는 이사 겸 주식 분석가로 근무했습니다. 그의 학력은 방갈로 의과대학에서 의학박사(MD)를, IIM 아마다바드에서 MBA를 취득했습니다.
이전 경력으로는 스위스 자산운용사에서 포트폴리오 관리, 바클레이즈와 골드만삭스 인도 헬스케어 부문에서 리더십 역할을 수행했습니다. 회장 겸 CEO인 로버트 베스만은 프라사드 박사의 알보텍 비즈니스 및 제품 파이프라인에 대한 깊은 이해가 회사 성장의 핵심 자산이라고 강조했습니다.
Alvotech (NASDAQ : ALVO), une entreprise biotechnologique mondiale spécialisée dans les médicaments biosimilaires, a nommé Dr Balaji V. Prasad au poste de Chief Strategy Officer. Le Dr Prasad apporte 25 ans d'expérience dans l'industrie pharmaceutique, combinant expertise médicale et formation en analyse financière. Il a précédemment occupé le poste de directeur et analyste actions chez Barclays, couvrant le secteur pharmaceutique spécialisé aux États-Unis. Il est titulaire d'un MD du Bangalore Medical College et d'un MBA de l'IIM Ahmedabad.
Ses expériences antérieures incluent la gestion de portefeuille dans une société suisse de gestion d'actifs ainsi que des postes de direction chez Barclays et dans la couverture santé de Goldman Sachs en Inde. Le président-directeur général Róbert Wessman a souligné que la profonde connaissance du Dr Prasad des activités et du pipeline produits d'Alvotech constitue un atout clé pour la croissance de l'entreprise.
Alvotech (NASDAQ: ALVO), ein globales Biotechnologieunternehmen mit Schwerpunkt auf Biosimilars, hat Dr. Balaji V. Prasad zum Chief Strategy Officer ernannt. Dr. Prasad bringt 25 Jahre Erfahrung in der Pharmaindustrie mit, wobei er medizinisches Fachwissen mit einem Hintergrund in Finanzanalyse kombiniert. Zuvor war er Direktor und Aktienanalyst bei Barclays und betreute den US-Spezialpharmasektor. Seine Qualifikationen umfassen einen MD vom Bangalore Medical College und einen MBA vom IIM Ahmedabad.
Frühere Positionen umfassen Portfoliomanagement bei einer Schweizer Vermögensverwaltung sowie Führungsrollen bei Barclays und der Gesundheitsabdeckung von Goldman Sachs in Indien. Vorsitzender und CEO Róbert Wessman hob hervor, dass Dr. Prasads tiefes Verständnis für Alvotechs Geschäft und Produktpipeline eine wichtige Grundlage für das Wachstum des Unternehmens darstellt.
- Appointment of experienced CSO with both medical and financial expertise
- New CSO brings extensive industry relationships across pharmaceutical, asset management and investment banking sectors
- Strategic hire who already has deep familiarity with company's business model and pipeline
- None.
REYKJAVIK, Iceland, March 27, 2025 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO, or the “Company”), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced the appointment of Dr. Balaji V. Prasad as Chief Strategy Officer.
A medical doctor by training, Dr. Prasad has 25 years' experience in the pharmaceutical industry, first as a consultant and subsequently as a financial and equities analyst focused on the specialty pharma and healthcare sectors. He was most recently a director and highly ranked equities analyst at Barclays, covering US specialty pharma and with Alvotech in his portfolio. He served previously as portfolio manager at a Swiss asset management firm focusing on global specialty pharma and generics and led Barclays' and Goldman Sachs' India healthcare coverage from Mumbai. He earned his MD from Bangalore Medical College and MBA from IIM Ahmedabad.
"It is a great pleasure to welcome Balaji onboard not only as a new member of the team, but one who has closely followed our growth and the evolution of our business and product pipeline," said Róbert Wessman, chairman and CEO of Alvotech. "He will be able to hit the ground running, helping to advance the business with his own expertise at the interface of medicine and therapeutics, and through his excellent relationships across the investment community."
"Alvotech is one of the most innovative and important companies in this critical space, and I am truly thrilled to be joining a company I have followed and admired," said Dr Prasad. "As a doctor and analyst of this space, I believe that biosimilars are key to delivering many of the amazing medicines that exist today to all of the people who need them. Alvotech is an incredibly exciting and focused business, and I will be putting my all into communicating the value of what we are doing to our growing circle of stakeholders in the US and globally - so we can deliver for patients and investors alike. I aim to bring my diverse experience across multiple continents and network encompassing the pharmaceutical, asset management and investment banking industries to drive Alvotech's goal of expanding affordable biologics globally."
About Alvotech
Alvotech is a biotech company, founded by Robert Wessman, focused solely on the development and manufacture of biosimilar medicines for patients worldwide. Alvotech seeks to be a global leader in the biosimilar space by delivering high quality, cost-effective products, and services, enabled by a fully integrated approach and broad in-house capabilities. Two biosimilars, to Humira® (adalimumab) and Stelara® (ustekinumab) are already approved and marketed in multiple global markets. The current development pipeline includes nine disclosed biosimilar candidates aimed at treating autoimmune disorders, eye disorders, osteoporosis, respiratory disease, and cancer. Alvotech has formed a network of strategic commercial partnerships to provide global reach and leverage local expertise in markets that include the United States, Europe, Japan, China, and other Asian countries and large parts of South America, Africa and the Middle East. Alvotech’s commercial partners include Teva Pharmaceuticals, a US affiliate of Teva Pharmaceutical Industries Ltd. (US), STADA Arzneimittel AG (EU), Fuji Pharma Co., Ltd (Japan), Advanz Pharma (EEA, UK, Switzerland, Canada, Australia and New Zealand), Dr. Reddy’s (EEA, UK and US), Biogaran (FR), Cipla/Cipla Gulf/Cipla Med Pro (Australia, New Zealand, South Africa/Africa), JAMP Pharma Corporation (Canada), Yangtze River Pharmaceutical (Group) Co., Ltd. (China), DKSH (Taiwan, Hong Kong, Cambodia, Malaysia, Singapore, Indonesia, India, Bangladesh and Pakistan), YAS Holding LLC (Middle East and North Africa), Abdi Ibrahim (Turkey), Kamada Ltd. (Israel), Mega Labs, Stein, Libbs, Tuteur and Saval (Latin America) and Lotus Pharmaceuticals Co., Ltd. (Thailand, Vietnam, Philippines, and South Korea). Each commercial partnership covers a unique set of product(s) and territories. Except as specifically set forth therein, Alvotech disclaims responsibility for the content of periodic filings, disclosures and other reports made available by its partners. For more information, please visit https://www.alvotech.com. None of the information on the Alvotech website shall be deemed part of this press release.
For more information, please visit our investor portal, and our website or follow us on social media on LinkedIn, Facebook, Instagram and YouTube.
ALVOTECH INVESTOR RELATIONS AND GLOBAL COMMUNICATIONS
Benedikt Stefansson, VP
alvotech.ir@alvotech.com
FAQ
Who is Dr. Balaji V. Prasad and what is his new role at Alvotech (ALVO)?
What experience does Alvotech's (ALVO) new Chief Strategy Officer bring to the company?
How will Dr. Prasad's appointment benefit Alvotech (ALVO)?
What is Alvotech's (ALVO) business focus?
